LAUSR

Among ST-segment elevation myocardial infarction (STEMI) patients, the respective impact of the baseline renal function, of the development of acute kidney injury (AKI), and of their combination, on the long-term cardiovascular outcomes, remain unclear. The present study was based on a post hoc analysis of the CIRCUS trial database, a multicentre randomized study which gathered 969 patients with anterior STEMI treated by primary percutaneous intervention (PPCI) within 12 hours of symptoms onset. Uni and multivariate regressions were performed to identify if the estimated glomerular filtration rate (eGFR) at admission and the development of AKI were associated with (1) cardiovascular death and heart failure (HF) at one year and (2) sub-optimal treatment prescription at discharge. A total of 822 patients were included. The mean baseline eGFR was 86 ± 19 mL/min/1.73m2. AKI occurred in 97 patients (11.8%). Baseline eGFR <60mL/min/1.73m2 was associated with HF (40.0 vs 16.8%, p<0.001) and with a sub-optimal treatment at discharge (35.9 vs 18.9%, p=0.001). AKI was associated with cardiovascular death (12.4 vs 2.8%, p<0.001), HF (50.5 vs 14.9%, p<0.001), and sub-optimal treatment (35.8 vs 18.5%, p<0.001). The multivariate analysis showed that AKI (OR=4.88, CI=2.89-8.27) and a lower baseline eGFR (OR=1.29 per 10mL/min/1.73m2 decrease, CI=1.11-1.50) are independent predictors of cardiovascular death or HF after anterior STEMI. In anterior STEMI patients undergoing PPCI, the development of AKI was the strongest independent predictor of poor clinical outcome at one year. The study suggests the need for a tailored monitoring of STEMI patients with AKI or baseline kidney dysfunction.